Skip to content

Study · Randomized controlled trial · n = 16 · 2022

4 results

A pilot clinical study to Evaluate Liraglutide-mediated Anti-platelet activity in patients with type-2 Diabetes (ELAID study).

Loganathan J, Cohen AC, Kaloupis GM, Harris C, Chronopoulos A, James V, Hamilton J, Green S, Wallis A, Morgan S, Dauer R, Gilfillan C, Dear AE

Journal of diabetes and its complications30 Mar 2022Cited by 11 (Europe PMC)

PMID35382966 (opens in a new tab)DOI10.1016/j.jdiacomp.2022.108188 (opens in a new tab)PepBankPUB-35382966
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, liraglutide transiently reduced the maximum slope of collagen-induced platelet aggregation versus placebo in the first week.

    In plain wordsIn adults with type 2 diabetes, liraglutide briefly reduced collagen-induced platelet clumping compared with placebo in the first week.

    Peptide
    Liraglutide
    Outcome
    DecreaseMaximum slope of platelet aggregation, collagen
    Study

    n = 16

    Comparator
    Placebo (saline)
    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    1.8 mg/day · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Liraglutide (n = 7) and placebo (n = 9) treated patients demonstrated normal platelet aggregation responses although transient and significant attenuation in maximum slope of platelet aggregation in response to collagen (p ≤ 0.05), arachidonic acid (p ≤ 0.05) and ADP (p ≤ 0.02) was observed in lirag…
    1 context sentence
    Summary · context
    A double-blind, placebo-controlled pilot study of 16 T2DM patients, 51-69 y/o, (mean age 60.4 y/o, 63.0% male) randomised to receive liraglutide (1.8 mg/day) or placebo (saline) for 6 months was conducted.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, liraglutide transiently reduced the maximum slope of arachidonic acid-induced platelet aggregation versus placebo in the first week.

    In plain wordsIn adults with type 2 diabetes, liraglutide briefly reduced arachidonic acid-induced platelet clumping compared with placebo in the first week.

    Peptide
    Liraglutide
    Outcome
    DecreaseMaximum slope of platelet aggregation, arachidonic acid
    Study

    n = 16

    Comparator
    Placebo (saline)
    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    1.8 mg/day · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Liraglutide (n = 7) and placebo (n = 9) treated patients demonstrated normal platelet aggregation responses although transient and significant attenuation in maximum slope of platelet aggregation in response to collagen (p ≤ 0.05), arachidonic acid (p ≤ 0.05) and ADP (p ≤ 0.02) was observed in lirag…
    1 context sentence
    Summary · context
    A double-blind, placebo-controlled pilot study of 16 T2DM patients, 51-69 y/o, (mean age 60.4 y/o, 63.0% male) randomised to receive liraglutide (1.8 mg/day) or placebo (saline) for 6 months was conducted.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, liraglutide transiently reduced the maximum slope of ADP-induced platelet aggregation versus placebo in the first week.

    In plain wordsIn adults with type 2 diabetes, liraglutide briefly reduced ADP-induced platelet clumping compared with placebo in the first week.

    Peptide
    Liraglutide
    Outcome
    DecreaseMaximum slope of platelet aggregation, ADP
    Study

    n = 16

    Comparator
    Placebo (saline)
    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    1.8 mg/day · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Liraglutide (n = 7) and placebo (n = 9) treated patients demonstrated normal platelet aggregation responses although transient and significant attenuation in maximum slope of platelet aggregation in response to collagen (p ≤ 0.05), arachidonic acid (p ≤ 0.05) and ADP (p ≤ 0.02) was observed in lirag…
    1 context sentence
    Summary · context
    A double-blind, placebo-controlled pilot study of 16 T2DM patients, 51-69 y/o, (mean age 60.4 y/o, 63.0% male) randomised to receive liraglutide (1.8 mg/day) or placebo (saline) for 6 months was conducted.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, platelet aggregation responses stayed normal in both liraglutide and placebo groups.

    In plain wordsIn adults with type 2 diabetes, platelet clumping stayed in the normal range with liraglutide and with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeOverall platelet aggregation responses
    Study

    n = 16

    Comparator
    Placebo (saline)
    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    1.8 mg/day · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Liraglutide (n = 7) and placebo (n = 9) treated patients demonstrated normal platelet aggregation responses although transient and significant attenuation in maximum slope of platelet aggregation in response to collagen (p ≤ 0.05), arachidonic acid (p ≤ 0.05) and ADP (p ≤ 0.02) was observed in lirag…
    1 context sentence
    Summary · context
    A double-blind, placebo-controlled pilot study of 16 T2DM patients, 51-69 y/o, (mean age 60.4 y/o, 63.0% male) randomised to receive liraglutide (1.8 mg/day) or placebo (saline) for 6 months was conducted.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.